Phase I Clinical Study on the Safety, Tolerability, and Pharmacokinetics of HRS-2261, the Effects of Food on the Pharmacokinetics of HRS-2261, and the Effects of HRS-2261 on CYP3A4 Metabolic Enzymes in Healthy Subjects After Single and Multiple Oral Administration
Latest Information Update: 07 Apr 2023
At a glance
- Drugs HRS-2261 (Primary)
- Indications Cough
- Focus Adverse reactions; First in man
- Sponsors Guangdong Hengrui Pharmaceutical
Most Recent Events
- 04 Apr 2023 Status changed from active, no longer recruiting to completed.
- 11 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 12 Apr 2022 Status changed from not yet recruiting to recruiting.